Nanobiotix S.A. (NBTX) NASDAQ
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Nanobiotix S.A.
Address
60 rue de Wattignies
Paris, IF 75012
France
Phone
33 1 40 26 04 70
Website
Sector
Healthcare
Industry
Biotechnology
Employees
100
First IPO Date
December 11, 2020
Key Executives
| Name | Title | Pay | Year Born |
| Laurent Levy | Co-Founder, President of the Executive Board & Chief Executive Officer | 973,646 | 1973 |
| Anne-Juliette Hermant | Chief People Officer & Member of Executive Board | 477,559 | 1974 |
| Bart Van Rhijn | Chief Financial & Business Officer and Member of Executive Board | 691,647 | 1974 |
| Louis Kayitalire | Chief Medical Officer & Member of Executive Board | 695,063 | 1959 |
| Earl J. Bergey | Co-Founder | 0 | 1955 |
| Brandon Owens | Vice President of Strategic Marketing & Corporate Communication | 0 | N/A |
| Anne-Sophie Lariviere | Chief Product Innovation & Delivery Officer | 0 | N/A |
| Margaret Galluzzi | Vice President & Global Head of Clinical Operations | 0 | N/A |
| Leonard A. Farber | Chief Clinical and Medical Affairs Officer & Chairman of the Scientific Advisory Board | 0 | N/A |
Description
Nanobiotix S.A. is a clinical-stage biotechnology firm focused on developing innovative therapeutic solutions for cancer. The company's leading experimental drug, NBTXR3, is a sterile aqueous suspension comprising crystalline hafnium oxide nanoparticles. This treatment is currently undergoing development for its potential application in a broad spectrum of cancers, including soft tissue sarcoma, various head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has established a strategic collaboration with LianBio for the development and commercialization of NBTXR3 within key Asian markets, specifically Greater China, South Korea, Singapore, and Thailand. Founded in 2003, the company's main operations are situated in Paris, France.
